{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-013783","form_type":"8-K","ticker":null,"cik":"0001695357","company_name":"Provention Bio, Inc.","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.085366+00:00","generated_at":"2026-06-16T09:07:32.070164+00:00","sec_items":["1.02","2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Sanofi completes acquisition of Provention Bio for $25.00 per share","bullets":["Tender offer expired with 74,490,556 shares tendered (~73% of outstanding); all accepted at $25.00 per share.","Merger completed under DGCL Section 251(h); each share converted to cash $25.00, net of withholding.","All outstanding Company Stock Options cancelled; holders receive cash for excess of $25.00 over exercise price.","Board replaced; Michael Tolpa, Olivier Bogillot, Debora Pellicano appointed directors; new officers named.","Company requested Nasdaq halt and delist; intends to deregister shares under Exchange Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-013783","json":"https://secwatch.observer/filing/0001493152-23-013783.json","markdown":"https://secwatch.observer/filing/0001493152-23-013783.md","text":"https://secwatch.observer/filing/0001493152-23-013783.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T09:07:32.070164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e544986c6","claim":"Rita Jain resigned as Director at Provention Bio, Inc..","evidence_excerpt":"each of the directors of the Company (Ashleigh Palmer; Avery Catlin; Rita Jain; John Jenkins; Wayne Pisano; and Nancy Wysenski) resigned from his or her respective position as a member of the Company’s board of directors, and any committee thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"12f4374165","claim":"Michael Tolpa was appointed as Director at Provention Bio, Inc..","evidence_excerpt":"Michael Tolpa, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company as the surviving corporation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"2487b7be62","claim":"Eleanor L. Ramos was appointed as Chief Medical Officer at Provention Bio, Inc..","evidence_excerpt":"(iv) Eleanor L. Ramos, Chief Medical Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"2876291e3a","claim":"Olivier Bogillot was appointed as President at Provention Bio, Inc..","evidence_excerpt":"(i) Olivier Bogillot, President","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"28fd34ed7a","claim":"Francisco Leon was appointed as Chief Scientific Officer at Provention Bio, Inc..","evidence_excerpt":"(iii) Francisco Leon, Chief Scientific Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"410e7bcc1a","claim":"Stacy Apgar was appointed as Assistant Secretary at Provention Bio, Inc..","evidence_excerpt":"(ix) Stacy Apgar, Assistant Secretary","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Assistant Secretary"}],"fact_type":"executive_change"},{"claim_id":"5b15c20981","claim":"Nancy Wysenski resigned as Director at Provention Bio, Inc..","evidence_excerpt":"each of the directors of the Company (Ashleigh Palmer; Avery Catlin; Rita Jain; John Jenkins; Wayne Pisano; and Nancy Wysenski) resigned from his or her respective position as a member of the Company’s board of directors, and any committee thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"69e1395a32","claim":"John Jenkins resigned as Director at Provention Bio, Inc..","evidence_excerpt":"each of the directors of the Company (Ashleigh Palmer; Avery Catlin; Rita Jain; John Jenkins; Wayne Pisano; and Nancy Wysenski) resigned from his or her respective position as a member of the Company’s board of directors, and any committee thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a25fffe5bd","claim":"Michael Tolpa was appointed as President at Provention Bio, Inc..","evidence_excerpt":"Michael Tolpa, the President and sole officer of Purchaser immediately prior to the Effective Time became the President and sole officer of the Company as the surviving corporation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"a2fde02a18","claim":"Benedict Osorio was appointed as Chief Quality Officer at Provention Bio, Inc..","evidence_excerpt":"(vi) Benedict Osorio, Chief Quality Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Quality Officer"}],"fact_type":"executive_change"},{"claim_id":"ae798b2d7e","claim":"Wayne Pisano resigned as Director at Provention Bio, Inc..","evidence_excerpt":"each of the directors of the Company (Ashleigh Palmer; Avery Catlin; Rita Jain; John Jenkins; Wayne Pisano; and Nancy Wysenski) resigned from his or her respective position as a member of the Company’s board of directors, and any committee thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"af757ef35f","claim":"Debora Pellicano was appointed as Vice President, Chief Financial Officer at Provention Bio, Inc..","evidence_excerpt":"(ii) Debora Pellicano, Vice President, Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Vice President, Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"b14fff3deb","claim":"Jamie Haney was appointed as Secretary at Provention Bio, Inc..","evidence_excerpt":"(viii) Jamie Haney, Secretary","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Secretary"}],"fact_type":"executive_change"},{"claim_id":"bd1b6048e7","claim":"Jason Hoitt was appointed as Chief Commercial Officer at Provention Bio, Inc..","evidence_excerpt":"(v) Jason Hoitt, Chief Commercial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"c57f27a14e","claim":"Ashleigh Palmer resigned as Director at Provention Bio, Inc..","evidence_excerpt":"each of the directors of the Company (Ashleigh Palmer; Avery Catlin; Rita Jain; John Jenkins; Wayne Pisano; and Nancy Wysenski) resigned from his or her respective position as a member of the Company’s board of directors, and any committee thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d151110ba8","claim":"Debora Pellicano was appointed as Director at Provention Bio, Inc..","evidence_excerpt":"Aventis, Inc., as the sole stockholder of the Company (“Aventis”), passed resolutions appointing Olivier Bogillot and Debora C. Pellicano as the sole directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d3b8dc92a3","claim":"Christina Yi was appointed as Chief Operations Officer at Provention Bio, Inc..","evidence_excerpt":"(vii) Christina Yi, Chief Operations Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operations Officer"}],"fact_type":"executive_change"},{"claim_id":"e381b8cce4","claim":"Avery Catlin resigned as Director at Provention Bio, Inc..","evidence_excerpt":"each of the directors of the Company (Ashleigh Palmer; Avery Catlin; Rita Jain; John Jenkins; Wayne Pisano; and Nancy Wysenski) resigned from his or her respective position as a member of the Company’s board of directors, and any committee thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f126445b30","claim":"Michael Tolpa was appointed as Treasurer at Provention Bio, Inc..","evidence_excerpt":"(x) Michael Tolpa, Treasurer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Treasurer"}],"fact_type":"executive_change"},{"claim_id":"fb8b672a11","claim":"Olivier Bogillot was appointed as Director at Provention Bio, Inc..","evidence_excerpt":"Aventis, Inc., as the sole stockholder of the Company (“Aventis”), passed resolutions appointing Olivier Bogillot and Debora C. Pellicano as the sole directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c9b35d2bb1a95b42555cc33c5a33a88aa52ebd3a","claim":"Provention Bio, Inc. underwent a change of control involving Sanofi S.A. for $25.00 per Share (closed 2023-04-27).","evidence_excerpt":"a tender offer (the “Offer”) to purchase all of the issued and outstanding shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company at a price of $25.00 per Share, to the seller in cash, without interest, but subject to any applicable withholding of taxes (the “Offer Price”) upon the terms and subject to the conditions set forth","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Sanofi S.A."},{"label":"Consideration","value":"$25.00 per Share"},{"label":"Closing","value":"2023-04-27"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}